Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...